香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容而產生或倚賴該等內容而引致之任何損失承擔任何責任。 SUNSHINE LAKE PHARMA CO., LTD. 廣 東 東 陽 光 藥 業 股 份 有 限 公 司 （在中華人民共和國註冊成立之股份有限公司） （股份代號：6887） 董事會會議通知 廣東東陽光藥業股份有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈， 董事會會議將於二零二五年八月二十九日（ 星期五 ）舉行，藉以（ 其中包括 ）審議及 批准本公司及其附屬公司截至二零二五年六月三十日止六個月的中期業績及其發 佈，以及考慮派付中期股息（ 如有 ）。 承董事會命 廣東東陽光藥業股份有限公司 董事長 張英俊博士 中國，東莞 二零二五年八月十九日 於 本 公 告 日 期 ， 執 行 董 事 為 張 英 俊 博 士 及 李 文 佳 博 士 ， 非 執 行 董 事 為 張 寓 帥 先 生、唐新發先生、朱英偉先生、曾學波先生、東 ...

Core Insights - The report highlights significant changes in the Hong Kong Stock Connect holdings, with notable increases and decreases in ownership percentages for various companies [1][2]. Group 1: Increased Holdings - 京城机电股份 (00187) saw the largest increase in holdings, up by 2.42%, bringing its total to 49.96% [2]. - 一脉阳光 (02522) experienced a 1.76% increase, resulting in a holding of 35.32% [2]. - 微盟集团 (02013) had a 1.13% increase, with a current holding of 33.76% [2]. - In the last five trading days, 长飞光纤光缆 (06869) had the highest increase at 4.25%, now holding 55.68% [4]. - FORTIOR TECHNOLOGY (SHENZHEN) CO., LTD. (01304) increased by 3.12%, reaching 6.02% [4]. Group 2: Decreased Holdings - 荣昌生物 (09995) experienced the largest decrease in holdings, down by 3.69%, now at 51.39% [2]. - 东阳光药 (06887) saw a reduction of 0.92%, with a holding of 47.90% [2]. - 山东墨龙 (00568) decreased by 0.88%, now at 56.49% [2]. - Over the last five trading days, 东阳光药 (06887) had the most significant drop at 5.14%, bringing its holding to 47.90% [4]. - 凯莱英 (06821) decreased by 4.46%, now holding 46.14% [4].

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [2] Core Views - The report highlights the release of the preliminary list of innovative drugs for commercial insurance, focusing on companies with leading clinical value and commercialization capabilities [4] - The pharmaceutical and biotechnology industry index increased by 2.21%, ranking 21st among 31 primary industries, underperforming the CSI 300 index which rose by 3.64% [5][16] - The report suggests a focus on companies in the oncology, metabolic diseases, and rare diseases treatment sectors, particularly those with strong clinical pipelines and commercialization capabilities [8] Industry Overview - The pharmaceutical and biotechnology industry PE (TTM, excluding negative values) as of August 15, 2025, is 31.38x, up from 30.97x in the previous period, indicating an upward valuation trend but still below the average [5][21] - The top three sub-industries by PE are vaccines (62.98x), hospitals (40.19x), and medical consumables (39.11x), while the lowest is pharmaceutical distribution (15.85x) [21] Important Industry News - The National Healthcare Security Administration (NHSA) has published the preliminary list of innovative drugs for commercial insurance, with over 100 innovative drugs included, covering areas such as oncology and rare diseases [8][26] - The NHSA is also advancing the reform of medical insurance payment methods, emphasizing a disease-based payment model to enhance the quality of healthcare services [30] Company Dynamics - Insmed's "Brensocatib" has received FDA approval for treating non-cystic fibrosis bronchiectasis, marking a significant advancement in targeted therapies for this condition [42][44] - Precigen's "Papzimeos" has been approved by the FDA as the first-in-class gene therapy for recurrent respiratory papillomatosis, providing a new treatment option for patients [48] - The approval of "博优平" (Dulaglutide injection) by 博安生物 marks it as the first domestically produced biosimilar of its kind, aiming to compete in the diabetes treatment market [49][50]

SUNSHINE LAKE PHARMA CO., LTD. 廣東東陽光藥業股份有限公司 (A joint stock company incorporated in the People's Republic of China with limited liability) （於中華人民共和國註冊成立的股份有限公司） (Stock Code 股份代號: 6887) Pursuant to Rule 2.07A of the Rules Governing the Listing of Securities (the "Listing Rules") on The Stock Exchange of Hong Kong Limited (the "Stock Exchange") under the expansion of paperless listing regime and electronic dissemination of corporate communications that came into effect on 31 December 2023, Sunshine Lake Pharm ...

SUNSHINE LAKE PHARMA CO., LTD. 廣東東陽光藥業股份有限公司 (A joint stock company incorporated in the People's Republic of China with limited liability) （於中華人民共和國註冊成立的股份有限公司） (Stock Code 股份代號: 6887) Dear registered shareholder(s), Arrangement of Electronic Dissemination of Corporate Communications Pursuant to Rule 2.07A of the Rules Governing the Listing of Securities (the "Listing Rules") on The Stock Exchange of Hong Kong Limited (the "Stock Exchange") under the expansion of paperless listing regime and electronic diss ...

Core Viewpoint - The innovative pharmaceutical sector has emerged as one of the strongest directions in the Hong Kong and A-share markets this year, driven by policy benefits, accelerated trends in overseas expansion of innovative drugs, and continuous capital investment [1] Group 1: Company Overview - Dongyangguang Pharmaceutical successfully listed on the Hong Kong main board on August 7, 2023, through a unique "absorption merger + introduction" method, marking a new paradigm for asset securitization among Chinese innovative pharmaceutical companies [1] - The company has a robust research and development team with over 1,100 personnel, including experienced scientists from multinational pharmaceutical companies [2] - Dongyangguang Pharmaceutical has established a comprehensive R&D platform and technical system over 20 years, covering various advanced technology fields [3] Group 2: Product Pipeline and Market Potential - The company currently has 150 approved drugs globally and over 100 drugs in development, including 49 first-class innovative drugs, showcasing a rich product reserve with several candidates having billion-dollar commercialization potential [3] - In the diabetes sector, Dongyangguang's insulin product is expected to be the first in China to be approved in the U.S. without phase III clinical trials, while its cancer drug has significant market potential with projected peak sales of $1 billion [4][5] - The company has seen a substantial increase in revenue from chronic disease treatment drugs, with projections indicating a rise from 5.17 billion yuan in 2022 to 10.68 billion yuan in 2024, nearly doubling its share of total revenue [6] Group 3: Strategic Developments - Dongyangguang Pharmaceutical has engaged in international licensing agreements, including a nearly $1 billion deal with Apollo for its HEC88473 project, indicating strong recognition of its R&D capabilities [5] - The company has a comprehensive production and sales network, with manufacturing bases that meet international standards and a sales network covering over 32 provinces in China and several countries abroad [6] - Following the merger with Dongyangguang Changjiang Pharmaceutical, the company has created a closed-loop system integrating R&D, production, and sales, enhancing its competitive advantage and accelerating new drug launches [7] Group 4: Future Outlook - With the ongoing advancement of its product pipeline and the expected launch of several new drugs with billion-dollar commercialization potential, Dongyangguang Pharmaceutical is poised for significant growth, aiming for a market capitalization of 100 billion yuan [9]

短短数日时间内，中国平安两次对保险同行出手。 8月11日，香港联交所官网披露，中国平安于8月11日以32.0655港元/股的价格买入中国太保H股股票， 耗资约5583.87万港元。本次交易后，中国平安持有中国太保H股比例由4.98%提升至5.04%，构成举 牌。 值得关注的是，这是险资时隔六年再次举牌同行。2019年，中国人寿曾两次增持中国太保H股，达到举 牌。此后的六年间，尽管险资举牌动作不断，但在保险同行中一直未有动作。 长江商报消息 ●长江商报记者 徐佳 2025年以来，险资举牌潮以空前态势席卷资本市场。 截至8月15日，险资在2025年内的举牌次数已经达到30次，大幅超过2024年全年的水平。其中，仅在8月 上半月，险资就已六次出手举牌上市公司。 长江商报记者注意到，本轮举牌潮中，险资举牌同行的现象时隔六年再次出现，中国平安在一周时间内 先后举牌中国太保、中国人寿H股。尽管中国平安对外回应称此举属于财务性投资，是险资权益投资组 合的常规操作，但这也折射出行业资产配置策略的深层变化。在利率下行周期，高股息保险股也被列 为"红利资产"，成为险资的重要选择。 同花顺数据显示，截至8月15日收盘，中国太保、中 ...

Group 1 - The market is currently in a critical verification phase for both domestic and international expectations, with a recent rise in the Hong Kong stock market driven by improved inflation expectations and strong earnings reports from leading companies [1] - As of August 15, 2025, 132 earnings forecasts were released for 550 major overseas Chinese stocks, with a positive forecast rate of 58%, particularly high in the utilities, financial, and healthcare sectors [2] - The overall earnings recovery for the first half of 2025 is expected to be 13%, compared to 8% in 2024, indicating significant industry differentiation [2] Group 2 - Short-term liquidity pressures exist in the market, but the medium-term outlook remains positive, with a projected net issuance of $1 trillion in U.S. Treasury bonds for Q3 2025, which may exert upward pressure on 10-year Treasury yields [3] - The Hong Kong stock market is experiencing a notable inflow of southbound funds, with recent inflows exceeding 30 billion HKD, indicating a strong interest from mainland investors [4] - The liquidity in the Hong Kong dollar remains relatively loose, with the total balance returning to levels seen before the Hong Kong Monetary Authority's intervention in May [4] Group 3 - The earnings forecast for the overseas Chinese stocks indicates a significant recovery potential, with the financial sector showing a positive outlook, particularly in banking and insurance [9] - The healthcare sector is also expected to see a positive earnings contribution, with a forecasted growth rate of 36% for 2025 [9] - The utilities sector has a forecasted positive growth rate of 19%, reflecting strong demand and favorable regulatory conditions [9]

Group 1 - The market is currently in a critical verification phase, with expectations for interest rate cuts in the US due to moderate inflation, leading to a rebound in market sentiment after previous recession concerns [1] - The Hong Kong stock market has seen a rapid rise, driven by strong earnings reports from major companies and supportive domestic policies, particularly in consumer lending [1] - The market is experiencing increased volatility, with a lack of clear trading themes and significant events pending verification, indicating a potential window for portfolio adjustments [1] Group 2 - As of August 15, 2025, 132 earnings forecasts were released for major overseas Chinese stocks, with a positive forecast rate of 58%, particularly high in utilities (100%), finance (89%), and healthcare (74%) sectors [2] - The overall profit recovery for the first half of 2025 is expected to be 13%, compared to 8% in 2024, with significant industry differentiation [2] - The recovery in profits is supported by improved liquidity in the Hong Kong market and stronger domestic policies compared to the previous year, with fiscal spending increasing by 8.9% year-on-year in the first half of 2025 [2] Group 3 - Short-term liquidity pressures exist in the market, but the medium-term outlook remains positive, with expectations for a net issuance of $1 trillion in US Treasury bonds in Q3 2025 [3] - The anticipated increase in bond issuance may exert upward pressure on 10-year Treasury yields, with a 92.1% probability of a rate cut in September [3] - The upcoming Jackson Hole meeting is crucial for discussions on monetary policy, which could impact market liquidity [3] Group 4 - Hong Kong's liquidity remains relatively ample, with significant inflows from southbound capital, which accounted for over 40% of trading in Hong Kong stocks [4] - The Hong Kong dollar has appreciated significantly, and the liquidity conditions are expected to remain relatively loose, despite potential adjustments in interest rates [4] - The market is currently experiencing a carry trade reversal, influenced by rising expectations for US interest rate cuts [4]

Group 1 - The core viewpoint of the news highlights the significant market interest in weight loss drugs, particularly following the IPO of Silver诺医药, which saw its market value exceed 26 billion HKD on its first trading day, marking it as one of the hottest IPOs of 2025 [1] - Silver诺医药's IPO was characterized by an oversubscription of 5,341.66 times, with subscription funds amounting to approximately 370 billion HKD, indicating strong investor demand [2] - The company focuses on innovative therapies for metabolic diseases, with its core product, a long-acting GLP-1 receptor agonist, set to launch in China for type 2 diabetes treatment in January 2025, and is currently undergoing clinical trials for obesity [2] Group 2 - Other Hong Kong-listed weight loss concept stocks also experienced significant gains, with派格生物医药 rising 32.45% and 九源基因 and 歌礼制药 both seeing increases of over 10% [1][3] - In the A-share market, companies like 博瑞医药 and 常山药业 have seen their stock prices double this year, reflecting a broader trend of rising interest in weight loss pharmaceuticals [1][3] - The global obesity issue is driving the pharmaceutical industry towards weight loss drugs, with projections suggesting that the GLP-1 drug market could exceed 150 billion USD by 2030, indicating a lucrative opportunity for domestic companies [4]